AT4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents
US7118747B2 · kind B2 · utility
4Cited by
1References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 30, 2003 |
| Grant date | Oct 10, 2006 |
| Priority date | — |
| Expiry date | Dec 14, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.